Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer

HOUSTON, July 16, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Alan Musso, Chief Financial Officer, will be leaving the Company effective August 31, 2018. Rosemary Williams, Bellicum’s Vice President of Finance and Controller, will serve as the Company’s interim principal accounting officer.

“On behalf of the entire company and our Board of Directors, I want to thank Alan for his dedication and significant contributions and wish him well as he moves on to a new opportunity,” stated Bellicum’s President & CEO Rick Fair. “With the recent financing, we are well capitalized to continue executing on our business plan and look forward to upcoming readouts on our clinical programs.”

Bellicum has initiated a search process to appoint a new CFO and Mr. Musso will provide support to the Company in a consultancy role during the transition.   

About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Forward-Looking Statement
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: , our capital needs and uses, our intentions and abilities to continue executing on our business plan and the upcoming readouts on our clinical programs. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2017 and our report on Form 10-Q for the quarter ended March 31, 2018. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Source: Bellicum Pharmaceuticals

Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com

Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@troutgroup.com

Primary Logo

Source: Bellicum Pharmaceuticals, Inc.